Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: Design of a pragmatic randomised non inferiority trial, the DRESS study

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Den Broeder, Alfons A ^a   Van Herwaarden, Noortje ^a   Van Der Maas, Aatke ^a   Van Den Hoogen, Frank H J ^a   Bijlsma, Johannes W ^b   Van Vollenhoven, Ronald F ^c   Van Den Bemt, Bart J F ^a  

^a Department of Rheumatology Sint Maartenskliniek ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anti TNF; Cost minimalisation; Decremental cost effectiveness ratio (DCER); Design; Discontinuation; Dose reduction; Non inferiority; Randomised controlled trial; Rheumatoid arthritis; Spacing

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; PREDNISONE;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; OPEN STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PRAGMATIC CLINICAL TRIALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885992327     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-299     Document Type: Article

References (46)

1. The GIP databank http://www.gipdatabank.nl/
2. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomised controlled trials. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V, JAMA 2006 295 2275 2285 10.1001/jama.295.19.2275 16705109 (Pubitemid 43736578)
3. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ, Ann Rheum Dis 2009 68 1177 1183 10.1136/ard.2008.094904 19019889
4. Editorial: dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA: evolving new paradigms. Den Broeder AA, van der Maas A, van den Bemt BJF, Rheumatology 2010 49 1801 1803 10.1093/rheumatology/ keq060 20332095
5. Relapse rates during the first year after withdrawal of anti-TNF treatment because of remission. Listing J, Strangfeld A, Kekow J, Hierse F, Stoyanova-Scholz M, et al. Ann Rheum Dis 2007 66 Suppl II 180 abstract
6. Infliximab and methotrexaat as induction therapy in patients with early rheumatoid arthritis. van der Bijl AE, Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Ten Wolde S, Han KH, et al. Arthritis & Rheum 2007 56 2129 2134 10.1002/art.22718 17599726 (Pubitemid 47173559)
7. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Nawata M, Saito K, Nakayamada S, Tanaka Y, Mod Rheumatol 2008 18 460 464 10.1007/s10165-008-0089-1 18535759
8. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA). Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, et al. Ann Rheum Dis 2010 69 1286 1291 10.1136/ard.2009.121491 20360136
9. Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, et al. Joint Bone Spine 2009 76 350 355 10.1016/j.jbspin.2008.11.009 19362504
10. Discontinuation of adalimumab without functional and radiographic damage progression after achieving sustained remission in patients with Rheumatoid arthritis (the HONOR study): 1 year results. Tanaka Y, Hirata S, Fukuyo S, Nawata M, Kubo S, et al. ACR 2012 64 s10 771 Abstract
11. Sustained effect after lowering high dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. van den Bemt BJF, Den Broeder AA, Snijders GF, Hekster YA, Van Riel PLCM, et al. Ann Rheum Dis 2008 67 1697 1701 10.1136/ard.2007.083683 18245109
12. Effects of low-dose etanercept in maintaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis. Botsios C, Furlan A, Ostuni P, Sfriso P, Todesco S, Punzi L, Ann Rheum Dis 2007 66 Suppl II 54 abstract
13. Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α den Broeder AA, Creemers MCW, van Gestel AM, van Riel PLCM, Rheumatology 2002 41 638 642 10.1093/rheumatology/ 41.6.638 12048289 (Pubitemid 34618881)
14. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. van der Maas A, Kievit W, van den Bemt BJ, van den Hoogen FH, van Riel PL, den Broeder AA, Ann Rheum Dis 2012 71 1849 1854 10.1136/annrheumdis- 2011-200945 22504561
15. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Lancet 2013 doi: 10.1016/S0140- 6736(12)61811-X
16. In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 Mg weekly or 25 Mg Weekly are both clinically superior to discontinuation: results from a randomized, 3-armed, double-blind clinical trial. van Vollenhoven RF, Leirisalo-Repo M, Uhlig T, Jansson M, Klackenberg A, ACR 2012 64 s12 10 Abstract
17. Maintenance of biological-free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Emery P, Smolen J, Kavanaugh A, van Vollenhoven RF, Pavelka K, Durez P, et al. Ann Rheum Dis 2011 70 suppl3 HU251b Abstract
18. Tapering TNF-blockers in established rheumatoid arthritis patients in DAS28 remission: results of a step-down strategy randomized controlled trial. Fautrel B, Pham T, Tubach F, Alfaiate T, Morel J, Dernis E, et al. ACR 2012 64 s12 7 Abstract
19. A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission. Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, et al. ACR 2012 64 s10 776 Abstract
20. Prevention of cartilage destruction by etanercept (PRECEPT) study: the comparison of joint destruction between low-dose and standard-dose etanercept in rheumatoid arthritis. Tadashi O, Yuko S, Kenji M, Shigeyuki W, Hiroaki N, Tatsuya K, ACR 2011 63 s10 405 Abstract
21. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, et al. Arthritis Rheum 2003 48 35 45 10.1002/art.10697 12528101 (Pubitemid 36091645)
22. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. N Engl J Med 2000 343 1586 1593 10.1056/NEJM200011303432201 11096165 (Pubitemid 32162981)
23. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, et al. Lancet 1994 22 344 1105 1110 (Pubitemid 24317629)
24. Dose escalation of infliximab in clinical practise: improvements seen may be explained by a regression-like effect. van Vollenhoven RF, Brannemark S, Klareskog L, Ann Rheum Dis 2004 63 426 430 10.1136/ard.2003.010967 15020338 (Pubitemid 38453310)
25. Much cheaper, almost as good: decrementally cost-effective medical innovation. Nelson AL, Cohen JT, Greenberg D, Kent DM, Ann Intern Med 2009 151 662 667 10.7326/0003-4819-151-9-200911030-00011 19884627
26. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arnett FC, Edworthy SM, Bloch DA, et al. Arthritis Rheum 1988 31 315 324 10.1002/art.1780310302 3358796 (Pubitemid 18091653)
27. Rheumatoid arthritis classification criteria an American college of rheumatology/European league against rheumatism collaborative initiative. Aletaha D, Neogi T, Silman AJ, et al. Arthritis Rheum 2010 2010 62 2569 2581
28. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring register. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, et al. Rheumatology (Oxford) 2011 50 196 203 10.1093/rheumatology/keq325 21078625
29. Patients acceptable symptom state (PASS) in Brazilian patients with rheumatoid arthritis: early versus established disease and physician perspective. Costa L, Guedes L, Schmitz M, Macedo P, Domiciano D, Laurindo I, ACR 2008 60 s10 1586 abstract
30. Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative. De Punder YM, Hendrikx J, den Broeder AA, Valls Pascual E, van Riel PL, Fransen J, J Rheumatol 2013 40 1268 1274 10.3899/jrheum.121438 23729803
31. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. van Hulst LT, Kievit W, van Riel PL, Fraenkel L, Arthritis Care Res (Hoboken) 2011 63 1407 1414 10.1002/acr.20551 21748861
32. Nederlandse vereniging voor reumatologie richtlijn 'Verantwoord gebruik van biologicals' (geautoriseerde versie januari 2011): Dutch society of rheumatology guidelin e 'Appropriate use of biologicals' authorizes version January 2011 and update http://www.nvr.nl/uploads/Y9/4Q/Y94Q-HUjQSe2RJ5SKasmEA/ Richtlijn-biologicals-geautorisateerde-versie-januari-2011.pdf and update http://www.nvr.nl/uploads/Y9/4Q/Y94Q-HUjQSe2RJ5SKasmEA/Richtlijn-biologicals- update-juli-2011.pdf
33. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Ann Rheum Dis 2009 68 954 960 10.1136/ard.2007.084459 18490431
34. Health assessment questionnaire modifications: is standardisation needed? Zandbelt MM, Welsing PM, van Gestel AM, et al. Ann Rheum Dis 2001 60 841 845 11502610 (Pubitemid 32778174)
35. How to read radiographs according to the Sharp/van der Heijde method. van der Heijde D, J Rheumatol 2000 27 261 263 10648051 (Pubitemid 30058662)
36. Common toxicity criteria http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm#ctc-40
37. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group, Health Policy 1990 1990 16 199 208
38. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. Welsing P, Borm GF, van Riel PLCM, J Rheum 2006 33 501 507 16511919 (Pubitemid 43334572)
39. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, et al. Arthritis Rheum 2002 46 913 920 10.1002/art.10190 11953967 (Pubitemid 34303802)
40. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. van der Maas A, Lie E, Christensen R, Choy E, de Man YA, van Riel P, Woodworth T, den Broeder AA, Ann Rheum Dis 2012 72 11 1800 1805 epub ahead 23178206
41. Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. den Broeder AA, Joosten LAB, Saxne T, Heinegard D, Fenner H, Miltenburg AMM, et al. Ann Rheum Dis 2002 61 311 318 10.1136/ard.61.4.311 11874832 (Pubitemid 34257741)
42. Chow SW, Shao J, Wong H, et al. Sample size calculations in clinical research New York: Chapman & Hall 2 2008 90
43. Wet van 26 februari 1998, houdende regelen inzake medisch wetenschappelijk onderzoek met mensen (Wet medisch wetenschappelijk onderzoek met mensen): laatstelijk gewijzigd bij Stb 2008 271 http://wetten.overheid.nl/ BWBR0009408/geldigheidsdatum-23-10-2013
44. DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use http://www.eortc.be/services/doc/clinical-eu-directive-04-april-01.pdf
45. Afbakening van geneesmiddelenonderzoek volgens de gewijzigde Wet Medisch-wetenschappelijk Onderzoek met Mensen (WMO). Vos EJ, Huitema ADR, Ned Tijdschr Geneeskd 2006 150 2104 2107 17036864 (Pubitemid 44492761)
46. Afbakening aanbevolen: geneesmiddelenonderzoek is in de WMO geen eenduidig begrip. Van Agt F, Medisch Contact 2007 62 1730 1731